EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial

Christoph Wanner iD, Masaomi Nangaku, Bettina J Kraus, Bernard Zinman, Michaela Mattheus, Stefan Hantel, Martin Schumacher, Kristin Ohneberg, Claudia Schmoor, Silvio E Inzucchi

Nephrology Dialysis Transplantation · 30.08.2024 · 39 (9) · 1504-1513

DOI: 10.1093/ndt/gfae032 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 06.02.2024. Verfasst von Christoph Wanner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Würzburg University Clinic, Würzburg, Germany. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Mechanisms underlying kidney benefits with sodium-glucose cotransporter-2 (SGLT2) inhibition in heart failure and/or type 2 diabetes (T2D) with established cardiovascular disease are currently unclear.

Methods

We evaluated post hoc the factors mediating the effect of empagliflozin on a composite kidney outcome (first sustained estimated glomerular filtration rate ≥40% reduction from baseline, initiation of renal replacement therapy or death due to kidney disease) in EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Variables, calculated as change from baseline or updated mean, were evaluated as time-dependent covariates and using a landmark approach (at Week 12) in Cox regression analyses. In multivariable analyses, variables with the greatest mediating effect were added using a step-up procedure.

Results

In univariable time-dependent updated mean covariate analyses, the strongest mediator was hematocrit (99.5% mediation). Hemoglobin, uric acid and urine albumin-to-creatinine ratio mediated 79.4%, 33.2% and 31.0%, respectively. Multivariable analyses were not performed due to the very strong mediation effect of hematocrit. In univariable Week 12 landmark change from baseline analyses, the strongest mediators included hematocrit (40.7%), glycated hemoglobin (28.3%), systolic blood pressure (16.8%) and free fatty acids (16.5%), which yielded a combined mediation of 78.9% in multivariable analysis.

Conclusions

Changes in hematocrit and hemoglobin were the strongest mediators of empagliflozin's kidney benefits in EMPA-REG OUTCOME participants with T2D and cardiovascular disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsDiabetes Mellitus, Type 2Glomerular Filtration RateGlucosidesSodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedCardiovascular DiseasesFollow-Up StudiesHeart FailureMediation AnalysisPrognosis

Stichwörter der Autor:innen

empagliflozinkidney diseasemediation analysissodium glucose co-transportertype 2 diabetes

Substanzen

Benzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Würzburg University Clinic, Würzburg, Germany.
  • Division of Nephrology and Endocrinology, Department of Hemodialysis and Apheresis, The University of Tokyo Hospital, Tokyo, Japan.
  • Medical Affairs, Boehringer Ingelheim International GmbH, Ingelheim, Germany.
  • Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany.
  • Comprehensive Heart Failure Centre, University of Würzburg, Würzburg, Germany.
  • Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.

ORCID-Profile: Christoph Wanner

Förderung

  • Boehringer Ingelheim
  • Eli Lilly and Company

Zitieren

APA

Wanner, C., Nangaku, M., Kraus, B. J., Zinman, B., Mattheus, M., Hantel, S., Schumacher, M., Ohneberg, K., Schmoor, C., & Inzucchi, S. E. (2024). How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial. Nephrology Dialysis Transplantation, 39(9), 1504-1513. https://doi.org/10.1093/ndt/gfae032

Vancouver

Wanner C, Nangaku M, Kraus BJ, Zinman B, Mattheus M, Hantel S, et al. How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial. Nephrology Dialysis Transplantation. 2024;39(9):1504-1513. doi:10.1093/ndt/gfae032

BibTeX
@article{Wanner2024,
  author = {Wanner, Christoph and Nangaku, Masaomi and Kraus, Bettina J and Zinman, Bernard and Mattheus, Michaela and Hantel, Stefan and Schumacher, Martin and Ohneberg, Kristin and Schmoor, Claudia and Inzucchi, Silvio E},
  title = {How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  volume = {39},
  number = {9},
  pages = {1504--1513},
  doi = {10.1093/ndt/gfae032}
}
Kostenlos starten →